View : 779 Download: 110

Use of CA15-3 for screening breast cancer: An antibody-lectin sandwich assay for detecting glycosylation of CA15-3 in sera

Title
Use of CA15-3 for screening breast cancer: An antibody-lectin sandwich assay for detecting glycosylation of CA15-3 in sera
Authors
Choi, Jae WoongMoon, Byung-InLee, Jun WooKim, Hyoung JinJin, YingjiKim, Hong-Jin
Ewha Authors
문병인이준우
SCOPUS Author ID
문병인scopusscopus; 이준우scopusscopus
Issue Date
2018
Journal Title
ONCOLOGY REPORTS
ISSN
1021-335XJCR Link

1791-2431JCR Link
Citation
ONCOLOGY REPORTS vol. 40, no. 1, pp. 145 - 154
Keywords
breast cancerbiomarkerCA15-3lectinMUC1glycosylation
Publisher
SPANDIDOS PUBL LTD
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Elevated serum CA15-3 assessed by enzyme-linked immunosorbent assay (ELISA) has been considered a diagnostic marker of breast cancer. However, accumulating data indicate that the current ELISA system for detecting CA15-3, which targets the peptide backbone of CA15-3, is not sufficiently sensitive to detect early or localized breast cancer. In the present study, we designed an antibody-lectin sandwich assay detecting glycosylation of CA15-3 in patients with breast cancer. Immobilized anti-CA15-3 monoclonal antibody captures CA15-3 in serum, and glycosylation of the CA15-3 is detected with Concanavalin A (ConA) lectin, which preferentially bind high-mannose N-glycans. ConA provided the best signal for detecting serum CA15-3 among 9 types of lectin, Since CA15-3 is a heavily glycosylated protein, detecting the glycosylation of CA15-3 should be a much more sensitive way to assess CA15-3 than the current ELISA method. Linear responses were obtained in the anti-CA15-3 antibody-ConA sandwich assay when sera were diluted up to 2000-fold. This dilution factor is comparable with that of the current ELISA system which allows 50- to 100-fold serum dilutions. The glycosylation level of CA15-3 was found to increase with increasing breast cancer stage in the sandwich assay. The assay system appeared to efficiently discriminate breast cancer stage I (sensitivity: 63%, specificity: 69%), IIA (sensitivity: 77%, specificity: 75%), IIB (sensitivity: 69%, specificity: 86%) and III (sensitivity: 80%, specificity: 65%) from benign breast disease. The antibody-lectin sandwich assay shows promise as a new prospect for the early detection of breast cancer.
DOI
10.3892/or.2018.6433
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
Use of CA15‑3 for screening breast cancer.pdf(844.25 kB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE